<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02353702</url>
  </required_header>
  <id_info>
    <org_study_id>2012/176/HP</org_study_id>
    <nct_id>NCT02353702</nct_id>
  </id_info>
  <brief_title>Efficacy of Local Anesthesic on Diaphragmatic Function After Upper Abdominal Surgery</brief_title>
  <acronym>CATPAR</acronym>
  <official_title>Efficacy of Parietal Continuous Infiltration of Local Anesthesic on Diaphragmatic Function After Upper Abdominal Surgery Through a Subcostal Incision</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Rouen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Rouen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Upper abdominal surgery is known to induce such pulmonary complications as pneumonia,
      atelectasis, pleural effusion. The post operative diaphragmatic dysfunction participates to
      these complications and lasts for 7 days after upper abdominal surgery. The sniff-test is a
      recognized tool for measuring the diaphragmatic function.The purpose of this study is to
      evaluate the effectiveness of parietal analgesia with continuous infiltration of local
      anesthesic on diaphragmatic function after upper abdominal surgery through a subcostal
      incision. Our main outcome is to measure the diaphragmatic function with the sniff test in 44
      patients with parietal infiltration of ropivacaine and in 44 patients with placebo. Our
      secondary outcomes are the evaluation of the effect of continuous parietal analgesia with
      ropivacaine on IPmax and EPmax, oxygen saturation, post operative pulmonary complications and
      post operative recovery. This prospective study will determine if the pre peritoneal local
      infiltration of ropivacaine is useful to decrease post operative diaphragmatic dysfunction.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 2014</start_date>
  <completion_date type="Actual">June 2017</completion_date>
  <primary_completion_date type="Actual">June 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Buccal Inspiratory Pression (IP) Evaluation of diaphragmatic function using sniff test.</measure>
    <time_frame>Day 6 post surgery</time_frame>
    <description>Evaluation of diaphragmatic function using sniff test. The measured value is buccal inspiratory pression.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximal buccal inspiratory pression (IPmax) using sniff test</measure>
    <time_frame>Day 6 after surgical procedure</time_frame>
    <description>Evaluation of maximal buccal inspiratory pression (IPmax) using sniff test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximal buccal expiratory pression (EPmax) using sniff test</measure>
    <time_frame>Day 6 after surgical procedure</time_frame>
    <description>Evaluation of maximal buccal expiratory pression (EPmax) using sniff test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oxygen saturation rate</measure>
    <time_frame>Day 6 after surgical procedure</time_frame>
    <description>Evaluation of Oxygen saturation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>medical complication outcome (pneumonia)</measure>
    <time_frame>week 6 after surgical procedure</time_frame>
    <description>Medical pulmonary complications outcome : pneumonia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>medical complication outcome (atelectasis)</measure>
    <time_frame>week 6 after surgical procedure</time_frame>
    <description>Medical pulmonary complications outcome : atelectasis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>medical complication outcome (pleural effusions)</measure>
    <time_frame>week 6 after surgical procedure</time_frame>
    <description>Medical pulmonary complications outcome : pleural effusions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Morphine consummation (Measurement of Morphine consummation since surgery)</measure>
    <time_frame>week 6 after surgical procedure</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">31</enrollment>
  <condition>Hepatectomy</condition>
  <arm_group>
    <arm_group_label>Infusion of Ropivacaine during 48 hours</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Evaluation of diaphragmatic function with Sniff test after 48h continuous parietal infiltration of Ropivacaine using parietal catheter at the following dose :
20 ml Bolus (7,5 mg/ml) then continuous administration of 10 ml per hour (2 mg/ml)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Infusion of placebo during 48 hours</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Evaluation of diaphragmatic function with Sniff test after 48h continuous parietal infiltration of placebo using parietal catheter at the following dose :
20 ml Bolus (NaCl 0.9 %) then continuous administration of 10 ml per hour (NaCl 0.9 %)</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Sniff test</intervention_name>
    <description>Evaluation of diaphragmatic function by sniff test after continuous parietal infusion of ropivacaine or placebo</description>
    <arm_group_label>Infusion of Ropivacaine during 48 hours</arm_group_label>
    <arm_group_label>Infusion of placebo during 48 hours</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Infusion of Ropivacaine during 48 hours</intervention_name>
    <description>20 ml Bolus (7,5 mg/ml) then continuous administration of 10 ml per hour (2 mg/ml) during 48 hours of Ropivacaine.
20 ml Bolus (NaCl 0.9 %) then continuous administration of 10 ml per hour, during 48 hours of NaCl 0.9 %.</description>
    <arm_group_label>Infusion of Ropivacaine during 48 hours</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Continuous parietal infusion with parietal catheter</intervention_name>
    <description>Continuous parietal infiltration of Ropivacaine or placebo</description>
    <arm_group_label>Infusion of Ropivacaine during 48 hours</arm_group_label>
    <arm_group_label>Infusion of placebo during 48 hours</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Infusion of placebo during 48 hours</intervention_name>
    <arm_group_label>Infusion of placebo during 48 hours</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NaCl</intervention_name>
    <arm_group_label>Infusion of Ropivacaine during 48 hours</arm_group_label>
    <arm_group_label>Infusion of placebo during 48 hours</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Surgical Indication for Upper abdominal surgery through subcostal incision

          -  More than 18 years old , less than 80 years old

          -  ASA score between 1 and 3

          -  Effective contraception for more than 3 months in women of childbearing age

          -  Patients signed an informed consent

          -  Affiliation to a social security regimen

        Exclusion Criteria:

          -  BMI more than 30 kg/m2

          -  Nasal obstruction during inclusion

          -  Preoperative treatment with morphine

          -  Need for a postoperative nasogastric tube

          -  Difficulty to understand the use of the PCA and/or the sniff-test

          -  Impossibility to place the catheter in preperitoneal position

          -  Pregnant women or breasting women

          -  Patients under guardianship

          -  Contraindication to use of ropivacaine

          -  Inclusion in another clinical trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michel SCOTTE, Pr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rouen University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Rouen University Hospital</name>
      <address>
        <city>Rouen</city>
        <zip>76031</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 22, 2015</study_first_submitted>
  <study_first_submitted_qc>February 2, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 3, 2015</study_first_posted>
  <last_update_submitted>August 21, 2017</last_update_submitted>
  <last_update_submitted_qc>August 21, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 22, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Diaphragmatic function</keyword>
  <keyword>sniff-test</keyword>
  <keyword>pulmonary complications</keyword>
  <keyword>upper abdominal surgery</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ropivacaine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

